Diagnosis for ALK Positive Non-small Cell Lung Cancer

Diagnosis for ALK Positive Non-small Cell Lung Cancer

The anaplastic lymphoma kinase (ALK) gene rearrangement is a driver gene of non-small cell lung cancer (NSCLC). Positive expression of ALK gene rearrangement has been considered a molecular subtype of NSCLC, that there are special pathological characteristics and clinical prognosis. Furthermore, the...

Full description

Bibliographic Details
Main Authors:	Qin FENG, Xin YANG, Dongmei LIN
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2015-02-01
Series:	Chinese Journal of Lung Cancer
Subjects:	Lung neoplasms Anaplastic lymphoma kinase Fluorescence in situ hybridization Immunohistochemistry Polymerase chain reaction
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2015.02.02

Similar Items

Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer
by: David R. Hout, et al.
Published: (2017-08-01)

The Research of Clinical Pathological Features of ALK Positive Lung Cancer  in 525 Patients and the Discussion of Detection Methods
by: Xiang ZHU, et al.
Published: (2014-03-01)

Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma
by: In Ho Choi, et al.
Published: (2015-07-01)

Immunohistochemistry and fluorescence in-situ hybridization study for detection of anaplastic lymphoma kinase gene rearrangement in nonsmall cell lung carcinoma
by: Mohamed Hantera, et al.
Published: (2018-01-01)

Discordance between Fluorescence In Situ Hybridization and Immunohistochemistry Analysis of Anaplastic Lymphoma Kinase Rearrangement in Indian Patients with Non-Small Cell Lung Cancer
by: Manish Kumar, et al.
Published: (2020-06-01)

Core Biopsy Diagnosis of ALK Positive Inflammatory Myofibroblastic Tumor of Lung: An Interesting Case
by: Ritesh SACHDEV, et al.
Published: (2020-05-01)

A Case Report: an EML4-ALK Positive Lung Adenocarcinoma Diagnosed  with Lymphoma Previously
by: Li LIU, et al.
Published: (2015-02-01)

Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib:  A Case Report and Literature Review
by: Haixiang YANG, et al.
Published: (2021-09-01)

Safety and Preliminary Efficacy of Ceritinib 450 mg with Food in Chinese ALK-positive Non-small Cell Lung Cancer
by: Yuke TIAN, et al.
Published: (2020-08-01)

Whole-process Management of Treatment of Advanced ALK Positive Non-small Cell Lung Cancer: A Case Report
by: Henan BAI, et al.
Published: (2021-08-01)

Treatment of Patients with ALK Gene Rearranged Non-small Cell Lung Cancer  after Resistance to Crizotinib
by: Tao JIANG, et al.
Published: (2015-02-01)

A New Target in Non-small Cell Lung Cancer: EML4-ALK Fusion Gene
by: Huijuan WANG, et al.
Published: (2011-06-01)

Economic Analysis of Alternative Strategies for Detection of ALK Rearrangements in Non Small Cell Lung Cancer
by: Shivang Doshi, et al.
Published: (2016-01-01)

Anaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumor with sarcomatous morphology and distant metastases: An unusual histomorphology and behavior
by: Bhawna Sethi, et al.
Published: (2015-01-01)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
by: Karachaliou N, et al.
Published: (2019-06-01)

RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance
by: Claudia Vollbrecht, et al.
Published: (2018-11-01)

Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer
by: Xin WANG, et al.
Published: (2018-09-01)

Advances in Drug Resistance Mechanisms and Prognostic Markers of Targeted Therapy in ALK-positive Non-small Cell Lung Cancer
by: Shasha WANG, et al.
Published: (2020-11-01)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
by: Chan-Young Ock, et al.
Published: (2019-09-01)

Microfluidics-based immunofluorescence for fast staining of ALK in lung adenocarcinoma
by: Saška Brajkovic, et al.
Published: (2018-10-01)

Analysis of EML4-ALK Gene Fusion Mutation in Patients  with Non-small Cell Lung Cancer
by: Xuzhou WANG, et al.
Published: (2015-02-01)

Clinical Efficacy of Crizotinib in Treatment of Patients with Advanced NSCLC
by: Emei GAO, et al.
Published: (2016-03-01)

Three years sustained complete remission achieved in a primary refractory ALK-positive anaplastic T large cell lymphoma treated with crizotinib
by: Carolina Valeria Mahuad, et al.
Published: (2016-06-01)

Destaining of Diff-Quik stained cytologic smears is not necessary for the detection of anaplastic lymphoma kinase gene rearrangement in lung adenocarcinoma by fluorescence in situ hybridization
by: Weisheng Xu, et al.
Published: (2016-01-01)

ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature
by: Nobuaki Mamesaya, et al.
Published: (2017-07-01)

Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 non-small-cell lung cancer patients from Kolkata: Using immunohistochemistry as the diagnostic modality in a significant subset
by: Koushik Chatterjee, et al.
Published: (2017-01-01)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
by: Barrows SM, et al.
Published: (2019-02-01)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
by: Qian Zhu, et al.
Published: (2017-06-01)

Dramatic response to alectinib in a patient with ALK‐rearranged squamous cell lung cancer
by: Jun Shiihara, et al.
Published: (2021-09-01)

Clinical, Conventional CT and Radiomic Feature-Based Machine Learning Models for Predicting ALK Rearrangement Status in Lung Adenocarcinoma Patients
by: Lan Song, et al.
Published: (2020-03-01)

Identification of a Novel SLC8A1-ALK Fusion and Non-Canonical Expression Significantly Responding to ALK-TKIs in Lung Adenocarcinoma: A Case Report
by: Zhu X, et al.
Published: (2021-09-01)

NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target
by: Elissa Andraos, et al.
Published: (2021-01-01)

ALK Positive Anaplastic Large Cell Lymphoma Presenting as Extensive Bone Involvement
by: Smeeta Gajendra, et al.
Published: (2015-01-01)

A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report
by: Kashima J, et al.
Published: (2016-10-01)

Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
by: Yu H, et al.
Published: (2019-08-01)

Systemic ALK-positive anaplastic large cell lymphoma involving implant site: a fortuitous association
by: Mayur Parkhi, et al.
Published: (2021-08-01)

Inflammatory Myofibroblastic Tumour of Thyroid with its Prominent Spindle Cell Pattern: A Rare Case Report
by: S. Marylilly, et al.
Published: (2016-04-01)

Anaplastic large cell lymphoma with cavernous sinus syndrome as first symptom
by: Wei-wei XU, et al.
Published: (2019-09-01)

MOLECULAR BIOLOGICAL CHARACTERISTICS OF ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA
by: E. V. Chernyshova, et al.
Published: (2017-01-01)

Prognostic Analysis of Patients with Advanced Non-small Cell Lung Cancer  in Different Genotypes
by: Ping LIU, et al.
Published: (2017-11-01)